Archives — June 2016 back to current month (4)
How Sick Will Brexit Make Biotech and Pharma? (06/29/2016)
In tandem with the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union. Given the uncertainty and dire economic forecasts, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry.
Maxim analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc., even though its product originated in the deep blue sea. With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore.
Soligenix Develops Defenses Against Bioterrorism (06/15/2016)
Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company.
Investment in Cell and Gene Therapies Ramps Up (06/08/2016)
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way.
|"INO announced a collaboration with Roche to evaluate their DNA-based immunotherapies in advanced bladder cancer."|
|"We view RVX's shares as undervalued, and in a position to provide long-term upside potential."|